The estimated Net Worth of Biocapital Advisors Lp Para... is at least $45.5 Millón dollars as of 1 August 2024. Biocapital Para owns over 2,400,000 units of Olema Pharmaceuticals stock worth over $9,663,676 and over the last few years Biocapital sold OLMA stock worth over $35,808,000.
Biocapital has made over 2 trades of the Olema Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Biocapital sold 2,400,000 units of OLMA stock worth $35,808,000 on 1 August 2024.
The largest trade Biocapital's ever made was selling 2,400,000 units of Olema Pharmaceuticals stock on 1 August 2024 worth over $35,808,000. On average, Biocapital trades about 1,250,000 units every 119 days since 2023. As of 1 August 2024 Biocapital still owns at least 783,118 units of Olema Pharmaceuticals stock.
You can see the complete history of Biocapital Para stock trades at the bottom of the page.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham y Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: